Breakingviews: Par for M&A course

The $8 bln sale of Par Pharmaceutical to Endo provides a clear window into a seller's market, explain Rob Cyran and Jeffrey Goldfarb.

from Reuters Video: Breakingviews http://ift.tt/1GjITj0
via IFTTT